Ustekinumab versus vedolizumab and ustekinumab versus tumor necrosis factor alpha agent infectious adverse effects in patients with ulcerative colitis, a real-world data study

Our findings demonstrate that ustekinumab is associated with a significantly lower risk of several infections. However, there is a less prominent difference in infectious risk when compared to vedolizumab. These results suggest that ustekinumab may offer a safer alternative, compared to anti-TNFα agents and possibly to vedolizumab, particularly those at higher risk of infections.

Authors

Institutions

Publication Details

Journal
Expert Opinion on Pharmacotherapy
Published
2025-09-18
DOI
https://doi.org/10.1080/14656566.2025.2564333
Primary Topic
Inflammatory Bowel Disease
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Ustekinumab versus vedolizumab and ustekinumab versus tumor necrosis factor alpha agent infectious adverse effects in patients with ulcerative colitis, a real-world data study

Daphne Moutsoglou, Muhammad Ali Butt, John Bassett, Abdellatif Ismail et al.
Expert Opinion on Pharmacotherapy
Inflammatory Bowel Disease
article

Ustekinumab versus vedolizumab and ustekinumab versus tumor necrosis factor alpha agent infectious adverse effects in patients with ulcerative colitis, a real-world data study

Daphne Moutsoglou, Muhammad Ali Butt, John Bassett, Abdellatif Ismail, Hussam Almasri, Himsikhar Khataniar, Rahul Karna
article en

Abstract

Our findings demonstrate that ustekinumab is associated with a significantly lower risk of several infections. However, there is a less prominent difference in infectious risk when compared to vedolizumab. These results suggest that ustekinumab may offer a safer alternative, compared to anti-TNFα agents and possibly to vedolizumab, particularly those at higher risk of infections.

Expert Opinion on PharmacotherapyVol. 26(13)
University of Minnesota (US), Sanford Health (US), University of North Dakota (US), Allegheny General Hospital (US), University of Minnesota System (US), Twin Cities Orthopedics (US), Lahey Medical Center (US), Minneapolis VA Medical Center (US), University of Maryland, College Park (US)
Openalex Percentile: Top 73%
Inflammatory Bowel Disease
DOISourceOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Ustekinumab versus vedolizumab and ustekinumab versus tumor necrosis factor alpha agent infectious adverse effects in patients with ulcerative colitis, a real-world data study — Daphne Moutsoglou, Muhammad Ali Butt, et al. · Expert Opinion on Pharmacotherapy (2025) | TGRS Research Map | TGRS